- Home
- GITS vs ENVB Comparison
GITS vs ENVB Comparison
Compare GITS & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | ENVB |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GITS | ENVB |
|---|---|---|
| Price | $0.71 | $5.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 40.3K | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,867.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $4.55 |
| 52 Week High | $9.78 | $96.30 |
Technical Indicators
Market Signals| Indicator | GITS | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 24.04 | 47.37 |
| Support Level | $0.71 | $4.55 |
| Resistance Level | $1.34 | $5.79 |
| Average True Range (ATR) | 0.12 | 1.29 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 0.00 | 6.44 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.